Ashurst advises Clinigen Group plc on its 1 billion recommended offer from Triton
08 December 2021
08 December 2021
Pursuant to the terms of the offer, Clinigen shareholders will receive 883 pence per share, valuing the issued and to be issued share capital of Clinigen at approximately £1.2 billion.
Clinigen is a global pharmaceutical Services and Products company focused on providing ethical access to medicines. Clinigen's mission is to deliver the right medicine to the right patient at the right time. The Clinigen Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Triton is a leading European private equity investment firm with a proven track record and deep expertise in investing in healthcare, including in pharmaceutical and pharmaceutical services companies.
The Ashurst team advising Clinigen is being led by Global Chair Karen Davies, assisted by senior corporate associates, Aimee Carroll-Hewitt and Sara Hamzawi, corporate associates Lauren Garrett, Aaron Koh and Ariella Moses and trainee solicitors Michael Utama and Ciaran Rutherfurd. Head of incentives Nicholas Stretch, counsel Rebecca Servian and associate Katharine Foster assisted on the share incentives aspects. Competition partner Steven Vaz also advised with assistance from senior associate Laura Carter and associates Lyudmyla Bashynska and Louisa Northover. Partner Lynn Dunne, associates Jack Allen, Fraser Collingham and Andrew Sims are advising on the scheme of arrangement. Tax partner Alexander Cox and associate Martin Voelker assisted on tax aspects, with employment Ruth Buchanan and associate Claire Bradbury also advising.